Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reuse of single-use devices

This article was originally published in The Gray Sheet

Executive Summary

Association of Disposable Device Manufacturers submits simulated direct final rule to FDA that would require reprocessors to comply with existing premarket regulations, rather than follow the separate three-tiered classification system outlined in FDA's proposed strategy, issued Nov. 2 (1"The Gray Sheet" Nov. 8, p. 3). While FDA would exempt reprocessed SUDs deemed "low-risk" from premarket requirements, ADDM maintains that makers of all reprocessed Class I and Class II SUDs should either be required to submit 510(k)s or file petitions for 510(k) exemption. ADDM's mock reg also would shorten FDA's proposed grace period for reprocessors - requiring PMAs for reprocessed Class III SUDs immediately, 510(k)s for Class II devices in six months, and for Class I devices in nine months

You may also be interested in...



Risk Classification Governs SUD Reprocessor Premarket Requirements - FDA

FDA's current resource levels are insufficient to carry out inspections of health care facilities that reprocess medical devices intended for single use, FDA staffers believe.

Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU

Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.

Edgewell Finds COVID Bright Side: Wet Ones On Way To Becoming ‘Little Mega-Brand’

Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel